Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7405599 | 0.98 | GBA1 (0.63) | GBA1SLC6A4SLC6A2MEN1CYP2D6 | |
| SCHEMBL1814200 | 0.89 | GBA1 (0.52) | GBA1SLC6A4SLC6A2TP53KDM1A | |
| Hydrochloric Acid SCHEMBL3552788 | 0.87 | GBA1 (0.50) | GBA1SLC6A4SLC6A2MEN1CYP2D6 | |
| SCHEMBL25133603 | 0.84 | GBA1 (0.66) | GBA1SLC6A4SLC6A2KDM1AEP300 | |
| Hydrochloric Acid SCHEMBL7403206 | 0.82 | GBA1 (0.63) | GBA1SLC6A4SLC6A2KMT2AKDM1A | |
| SCHEMBL19302171 | 0.81 | KEAP1 (0.45) | GBA1HRH3KDM4ELMNAMAPT | |
| SCHEMBL4244293 | 0.81 | MAOB (0.53) | GBA1SLC6A4SLC6A2MEN1CYP2D6 | |
| SCHEMBL21799757 | 0.80 | GBA1 (0.66) | GBA1SLC6A4EP300HRH4HRH3 | |
| SCHEMBL3967185 | 0.80 | GBA1 (0.55) | GBA1SLC6A4SLC6A2HRH4HRH3 | |
| SCHEMBL15718702 | 0.80 | GBA1 (0.66) | GBA1SLC6A4EP300HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| EP-3793990-B1 | ANTIBACTERIAL COMPOUNDS | INFEX THERAPEUTICS LTD (GB) | 2023-07-19 | — | — | EP | disclosed |
| US-11524938-B2 | Aromatic sulfonamide derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-13 | — | — | US | disclosed |
| CN-113214140-B | Piperidine amide derivative, pharmaceutical composition and application thereof | 江苏谛奇医药科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| CN-113214139-B | Piperidine amide derivative, preparation method thereof, pharmaceutical composition thereof, single crystal culture method thereof and application thereof | 江苏谛奇医药科技有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-113214139-A | Piperidine amide derivative, preparation method thereof, pharmaceutical composition thereof, single crystal culture method thereof and application thereof | 江苏谛奇医药科技有限公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-1089735-A1 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | Warner-Lambert Company LLC (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6124323-A | ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS | WARNER-LAMBERT COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| WO-2000000197-A1 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| EP-0869792-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0869792-A2 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5773437-A | UROGENITAL DISORDERS SUCH AS DYSURIA | NIPPON CHEMIPHAR CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| WO-1997023458-A1 | SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997023216-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
| US-5034401-A | Cardiovascular disorders or antiischemia agents | SYNTHELABO (FR) | 1991-07-23 | — | — | US | disclosed |
| US-4690931-A | IN TREATMENT OF ANOXIA OR BRAIN DAMAGE | SYNTHELABO (FR) | 1987-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | GBA1 336/4885SLC6A4 1383/4885SLC6A2 1215/4885 |
| US-11524938-B2 | Aromatic sulfonamide derivatives | ARSA, SULT2A1, TPST2 | GBA1 143/4885SLC6A4 2254/4885SLC6A2 2877/4885 |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | GBA1 2356/4885SLC6A4 452/4885SLC6A2 1927/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | GBA1 2356/4885SLC6A4 452/4885SLC6A2 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.